SUPRIYA LIFESCIENCE LTD.
Creating true values that bind global health

Date: January 5, 2024

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Supriya Lifesciences Limited received GMP certification from ANVISA Brazil

Pursuant to the relevant provisions of the SEBI Listing Regulations, we are enclosing herewith Press Release "Supriya Lifesciences Limited received GMP certification from ANVISA Brazil".

Request you to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

SHWETA SHIVDHARI SINGH

Digitally signed by SHWETA SHIVDHARI SINGH
Date: 2024.01.05 14:44:18 +05'30'

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: **supriya@supriyalifescience .com** Website: **www.supriyalifescience.com**

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

SUPRIYA LIFESCIENCE LTD.

Supriya Lifesciences Limited received GMP certification from ANVISA Brazil

Mumbai 5th January 2024 – Supriya Lifescience Limited is pleased to announce that its manufacturing site in Lote Parshuram has received Good Manufacturing Practice (GMP) certification from the Regulatory Authority of Brazil, ANVISA.

Supriya Lifescience Limited, represented by its Chairman and Managing Director proudly announced that their Lote Factory passed the Brazilian Good Manufacturing Practice (GMP) inspection with a flawless "Zero" Observation in terms of Compliance. This success in the rigorous GMP inspection underscores Supriya's commitment to the highest quality standards and the excellence of its smart manufacturing practices.

The clearance of this audit marks the successful registration of 8 APIs with CADIFA and will further enable smoother and faster registration of the company's other APIs.

This Successful Inspection paves the way for Supriya Lifescience Ltd. to acquire more customers in the Brazilian Pharmaceutical market.

Brazil's GMP review is known to be challenging, involving stringent requirements. ANVISA actively conducts on-site inspections overseas, meticulously examines not only pharmaceutical quality management on-site but also data integrity, manufacturing facilities, and compliance with GMP in production processes. Within the industry, passing Brazil's GMP without any issues is publicly recognized as a difficult task, and achieving a flawless inspection is considered a remarkable accomplishment.

About Supriya Lifescience Ltd:

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by the USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and is headquartered in Mumbai, India.

Backed by strong R&D, 14 active USDMFs, 8 active CEPs and worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company's focus is to develop APIs and Intermediates for both Innovators and generic companies and we also partner exclusively as CDMO.

For more details:

Supriya Lifescience Ltd	**Dentsu Creative PR**
Krishna Raghunathan	Abhishek Chawande
T: 022-4033 2749	M: 9664516774
e-mail: cfo@supriyalifescience.com	e-mail: abhishek.chawande@dentsu.com